MDM2 SNP309 polymorphism contributes to endometrial cancer susceptibility: evidence from a meta-analysis
暂无分享,去创建一个
Shan Li | Junrong Wu | Qi-liu Peng | X. Qin | A. Qin | Cuiju Mo | Zhi-ping Chen | Limin Zhai | Shi Yang | Jing-zhe Sui | X. Lao
[1] Kiyoko Kato,et al. Association of MDM2 SNP309 and TP53 Arg72Pro polymorphisms with risk of endometrial cancer , 2013, Oncology reports.
[2] H. Romanowicz,et al. Association between MDM2 SNP309 polymorphism and endometrial cancer risk in Polish women. , 2012, Polish journal of pathology : official journal of the Polish Society of Pathologists.
[3] P. Lønning,et al. SNP285C modulates oestrogen receptor/Sp1 binding to the MDM2 promoter and reduces the risk of endometrial but not prostatic cancer. , 2012, European journal of cancer.
[4] R. Leng,et al. UBE4B, a ubiquitin chain assembly factor, is required for MDM2-mediated p53 polyubiquitination and degradation , 2011, Cell cycle.
[5] B. Kong,et al. MDM2 SNP309 is associated with endometrial cancer susceptibility: a meta-analysis , 2011, Human Cell.
[6] C. Prives,et al. The C-terminus of p53 binds the N-terminal domain of MDM2 , 2010, Nature Structural &Molecular Biology.
[7] S. Noda,et al. Polymorphisms of p53 codon 72 and MDM2 promoter 309 and the risk of endometrial cancer , 2009, Human Cell.
[8] S. Noda,et al. Murine double-minute 2 homolog single nucleotide polymorphism 309 and the risk of gynecologic cancer , 2009, Human Cell.
[9] R. Scott,et al. Polymorphisms in TP53 and MDM2 combined are associated with high grade endometrial cancer. , 2009, Gynecologic oncology.
[10] D. Vergara,et al. Hormonal carcinogenesis and socio‐biological development factors in endometrial cancer: A clinical review , 2008, Acta obstetricia et gynecologica Scandinavica.
[11] E. Taioli,et al. Endometrial hyperplasia, endometrial cancer and prevention: gaps in existing research of modifiable risk factors. , 2008, European journal of cancer.
[12] K. Lu,et al. Genetic polymorphisms and endometrial cancer risk , 2008, Expert review of anticancer therapy.
[13] J. Buring,et al. MDM2 SNP309 Is Associated with Endometrial Cancer Risk , 2008, Cancer Epidemiology Biomarkers & Prevention.
[14] G. Lane. Obesity and gynaecological cancer , 2008, Menopause international.
[15] Nikolaos A Patsopoulos,et al. Uncertainty in heterogeneity estimates in meta-analyses , 2007, BMJ : British Medical Journal.
[16] Carl W. Miller,et al. Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk. , 2007, Gynecologic oncology.
[17] S. Zienolddiny,et al. Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer , 2006, International journal of cancer.
[18] A. Levine,et al. MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. , 2006, Cancer research.
[19] Thomas A Trikalinos,et al. Impact of violations and deviations in Hardy-Weinberg equilibrium on postulated gene-disease associations. , 2006, American journal of epidemiology.
[20] J. W. Kim,et al. Single nucleotide polymorphism: a new risk factor for endometrial cancer? , 2005, Future oncology.
[21] Patrick Neven,et al. Endometrial cancer , 2005, The Lancet.
[22] Ammarin Thakkinstian,et al. Systematic review and meta-analysis of the association between {beta}2-adrenoceptor polymorphisms and asthma: a HuGE review. , 2005, American journal of epidemiology.
[23] J. Ioannidis,et al. Hardy–Weinberg equilibrium in genetic association studies: an empirical evaluation of reporting, deviations, and power , 2005, European Journal of Human Genetics.
[24] Y. Haupt,et al. Mdm2 in growth signaling and cancer , 2005, Growth factors.
[25] A. Levine,et al. A Single Nucleotide Polymorphism in the MDM2 Promoter Attenuates the p53 Tumor Suppressor Pathway and Accelerates Tumor Formation in Humans , 2004, Cell.
[26] Ian Purvis,et al. Detection of genotyping errors by Hardy–Weinberg equilibrium testing , 2004, European Journal of Human Genetics.
[27] D. Altman,et al. Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.
[28] H. Kinyamu,et al. Estrogen Receptor-Dependent Proteasomal Degradation of the Glucocorticoid Receptor Is Coupled to an Increase in Mdm2 Protein Expression , 2003, Molecular and Cellular Biology.
[29] S. Safe,et al. Estrogen receptor/Sp1 complexes are required for induction of cad gene expression by 17beta-estradiol in breast cancer cells. , 2003, Endocrinology.
[30] J. Blaydes,et al. p53-independent activation of the hdm2-P2 promoter through multiple transcription factor response elements results in elevated hdm2 expression in estrogen receptor alpha-positive breast cancer cells. , 2003, Cancer research.
[31] Aravinda Chakravarti,et al. Undetected genotyping errors cause apparent overtransmission of common alleles in the transmission/disequilibrium test. , 2003, American journal of human genetics.
[32] S. Thompson,et al. Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.
[33] G. Smith,et al. Bias in meta-analysis detected by a simple, graphical test , 1997, BMJ.
[34] N. Laird,et al. Meta-analysis in clinical trials. , 1986, Controlled clinical trials.
[35] W. Haenszel,et al. Statistical aspects of the analysis of data from retrospective studies of disease. , 1959, Journal of the National Cancer Institute.
[36] P. Lønning,et al. MDM2 SNP309 and risk of endometrial cancer. , 2013, Polish journal of pathology : official journal of the Polish Society of Pathologists.
[37] A. Nardulli,et al. Cell- and ligand-specific regulation of promoters containing activator protein-1 and Sp1 sites by estrogen receptors alpha and beta. , 2005, The Journal of biological chemistry.
[38] S. Safe. Transcriptional activation of genes by 17 beta-estradiol through estrogen receptor-Sp1 interactions. , 2001, Vitamins and hormones.